Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesenchymal stem cells (Nanfang Hospital, Southern Medical University)
- Development stage
- Unknown
- Lead developer
- Nanfang Hospital, Southern Medical University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of ex vivo-expanded mesenchymal stem cells (MSCs) derived from HLA-mismatched bone marrow. Developed by Nanfang Hospital of Southern Medical University, the therapy is being evaluated for the treatment of engraftment failure (graft failure) following autologous hematopoietic stem cell transplantation (auto-HSCT). MSCs are multipotent stem cells characterized by their immunomodulatory, anti-inflammatory, and regenerative properties. They express specific surface markers including CD29, CD44, CD73, CD90, CD105, and CD166, and are capable of differentiating into osteogenic, adipogenic, and chondrogenic lineages. In the context of hematopoietic transplantation, these cells are intended to support the recovery of the bone marrow microenvironment and facilitate the engraftment of hematopoietic stem cells.
- Other names
- BM-MSCsbone marrow-derived mesenchymal stem cellsHLA-mismatched bone marrow-derived mesenchymal stem cellsex-vivo-expanded BM-drived mesenchymal stem cells
Beyond the preview
Go deeper on mesenchymal stem cells (Nanfang Hospital, Southern Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesenchymal stem cells (Nanfang Hospital, Southern Medical University).